Modified antigen binding molecules with altered cell signaling activity
    5.
    发明申请
    Modified antigen binding molecules with altered cell signaling activity 审中-公开
    具有改变的细胞信号传导活性的修饰的抗原结合分子

    公开(公告)号:US20070071745A1

    公开(公告)日:2007-03-29

    申请号:US11509842

    申请日:2006-08-25

    IPC分类号: A61K39/395 C07K16/18

    摘要: The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having altered ability to mediate cell signaling activity by a target antigen, and/or altered ability to mediate cross-linking of one or more target antigens. In addition, the present invention relates to nucleic acid molecules encoding such modified ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the modified ABMs of the invention, and to methods of using these modified ABMs in treatment of disease. In addition, the present invention relates to modified ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

    摘要翻译: 本发明涉及修饰的抗原结合分子(ABM)。 在具体实施方案中,本发明涉及重组单克隆抗体或片段,包括嵌合,灵长类或人源化抗体或片段,具有改变的能力以介导目标抗原的细胞信号传导活性,和/或改变的介导一种 或更多的靶抗原。 此外,本发明涉及编码这种修饰的ABM的核酸分子以及包含这种核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的修饰的ABM的方法,以及使用这些修饰的ABM在治疗疾病中的方法。 此外,本发明涉及具有改进的治疗性质的具有改性糖基化的修饰的ABM,包括具有增加的Fc受体结合和增加的效应子功能的抗体。

    Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
    6.
    发明申请
    Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof 有权
    结合EGFR的抗原结合分子,编码相同的载体及其用途

    公开(公告)号:US20090232817A9

    公开(公告)日:2009-09-17

    申请号:US11892010

    申请日:2007-08-17

    摘要: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

    摘要翻译: 本发明涉及抗原结合分子(ABM)。 在具体实施方案中,本发明涉及重组单克隆抗体,包括对人EGFR特异的嵌合,灵长类或人源化抗体。 此外,本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外,本发明涉及具有改善的治疗性质的具有改性糖基化的ABM,包括具有增加的Fc受体结合和增加的效应子功能的抗体。

    Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
    7.
    发明申请
    Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function 审中-公开
    针对MCSP并具有增加的Fc受体结合亲和力和效应子功能的抗原结合分子

    公开(公告)号:US20060223096A1

    公开(公告)日:2006-10-05

    申请号:US11388204

    申请日:2006-03-24

    摘要: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human MCSP. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

    摘要翻译: 本发明涉及抗原结合分子(ABM)。 在具体实施方案中,本发明涉及重组单克隆抗体,包括对人MCSP特异性的嵌合,灵长类或人源化抗体。 此外,本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外,本发明涉及具有改善的治疗性质的具有改性糖基化的ABM,包括具有增加的Fc受体结合和增加的效应子功能的抗体。

    Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
    9.
    发明申请
    Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof 有权
    结合EGFR的抗原结合分子,编码相同的载体及其用途

    公开(公告)号:US20080279858A9

    公开(公告)日:2008-11-13

    申请号:US11348526

    申请日:2006-02-07

    摘要: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

    摘要翻译: 本发明涉及抗原结合分子(ABM)。 在具体实施方案中,本发明涉及重组单克隆抗体,包括对人EGFR特异的嵌合,灵长类或人源化抗体。 此外,本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外,本发明涉及具有改善的治疗性质的具有改性糖基化的ABM,包括具有增加的Fc受体结合和增加的效应子功能的抗体。